From the Research
The duration of Eliquis (apixaban) treatment for a 64-year-old female after a pulmonary embolism should be indefinite, as the benefits of extended anticoagulation in reducing the risk of recurrent venous thromboembolism outweigh the risks of bleeding, according to the most recent and highest quality study 1.
Key Considerations
- The decision to extend anticoagulation should be made on an individual basis, taking into account the patient's risk factors for recurrent venous thromboembolism and bleeding 2.
- The standard dose of Eliquis for pulmonary embolism treatment is 10mg twice daily for the first 7 days, followed by 5mg twice daily thereafter 3.
- Regular follow-up with a healthcare provider is essential to assess the risk-benefit ratio of continuing treatment and to monitor for signs of bleeding or recurrent clots 4.
Risk Factors to Consider
- Provoked vs. unprovoked pulmonary embolism
- Ongoing risk factors for venous thromboembolism, such as cancer or immobilization
- Personal and family history of clotting disorders
- Other medical conditions, such as kidney or liver disease
- Bleeding risk factors, such as age, hypertension, or concomitant use of antiplatelet agents
Evidence Summary
The most recent and highest quality study 1 compared the effectiveness and safety of apixaban and rivaroxaban in preventing recurrent venous thromboembolism and major bleeding events in patients with venous thromboembolism. The study found that apixaban was associated with a decreased risk of recurrent venous thromboembolism and major bleeding events compared to rivaroxaban. Another study 2 reviewed the results of preclinical and healthy volunteer studies, large phase III trials, and key studies that led to apixaban's current licensing, and found that apixaban offers several advantages over historical therapy for the treatment and secondary prevention of venous thromboembolism.